IDH1 and glioblastoma: The 2016 WHO classification of CNS tumors is based on “integrated diagnosis” including histology and isocitrate dehydrogenase (IDH)-1/2 mutations (a biomarker for secondary GBM), and the presence of the 1p/19q codeletion (a marker for oligodendroglioma) [110].